Visual Impairment Expected to Rise Significantly by 2050

This article originally appeared here.
Share this content:
Visual Impairment Expected to Rise Significantly by 2050
Visual Impairment Expected to Rise Significantly by 2050

FRIDAY, May 20, 2016 (HealthDay News) -- As baby boomers age, the number of Americans with visual impairment and blindness is expected to double over the next three decades, according to a study published online May 19 in JAMA Ophthalmology.

Researchers analyzed data on men and women aged 40 and older from six studies on vision loss and blindness, then estimated the prevalence of these issues through 2050. U.S. Census data was used to project vision impairment and blindness by age, sex, race and ethnicity, and state. In 2015, slightly more than 12 million Americans had a vision impairment. But by 2050, that number will rise to 25 million, the researchers predicted. In 2015, whites, women, and older adults had the highest prevalence of visual impairment, and it is predicted that will still be the case in 2050.

By 2050, the highest prevalence of visual impairment among minorities will shift from blacks -- 15.2 percent in 2015 to 16.3 percent in 2050 -- to Hispanics -- 9.9 percent in 2015 to 20.3 percent in 2050. The researchers also estimated that people in Florida and Hawaii will have the highest prevalence of visual impairment, and people in Mississippi and Louisiana will have the highest prevalence of blindness. Also predicted by 2050: Two million Americans will struggle with blindness; seven million will have glaucoma, or age-related macular degeneration; and 16 million will have the wrong eyeglasses.

"This study gives us a GPS for our nation's future eye health," lead researcher Rohit Varma, M.D., M.P.H., a professor of ophthalmology at the University of Southern California Keck School of Medicine in Los Angeles, told HealthDay. "The earlier we can diagnose and treat potentially blinding eye diseases, the greater the likelihood that more people will have the chance to live longer lives without the physical limitations and emotional challenges of vision loss."

Abstract
Full Text

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions


Sign up for myCME e-newsletters


More in Home

ASH: Anti-CD19 CAR T-Cell Tx Beneficial in B-Cell Lymphomas

ASH: Anti-CD19 CAR T-Cell Tx Beneficial in B-Cell ...

Second study shows benefit in relapsed or refractory B-cell lymphoma, follicular lymphoma

ASH: AAVD Beats ABVD for Advanced Hodgkin's Lymphoma

ASH: A+AVD Beats ABVD for Advanced Hodgkin's Lymphoma

Lower combined risk of progression, death, or noncomplete response with A+AVD

ASH: High-Dose Gene Transfer Beneficial in Severe Hemophilia A

ASH: High-Dose Gene Transfer Beneficial in Severe Hemophilia ...

Factor VIII gene transfer tied to sustained normalization of factor VIII activity levels

is free, fast, and customized just for you!

Already a member?

Sign In Now »